The Synthetic Biology Innovation Network

Biopharma

Biopharma

Editors' picks

SynBioBeta 2021 is Pushing to January 25-27, 2022

The COVID lemons keep coming, which means we get to keep making delicious lemonade! While SynBioBeta is beyond excited to host our global bioeconomy reunion conference, the current Delta variant conditions and...

An Open Letter from SynBioBeta CEO

Letter From the Editor: Leading the Future Is Never Easy

Last night, Zymergen, one of the first biology unicorns, announced that they would not generate revenues through 2022 and that their CEO was stepping down. Zymergen’s stock promptly fell 70% in after-hours trading. But...

Investors Bet Big with Fungi Alternative Protein Company Enough

Is Tissue Engineering The Future of Cruelty-Free Fashion?

So You Want to Sell Your Genome As an NFT? Read This First

In the past few months, non-fungible tokens, or NFTs, have become the hot new investment trend, generating skepticism, confusion, and millions of dollars. Jack Dorsey, the founder and CEO of Twitter, auctioned off his...

The Search for a Cancer Vaccine: Have We Been Doing It All Wrong?

Can Microbes Clean The World’s Most Polluted Waterways?

Water is arguably the most important resource in the world, and protecting it is crucial to our survival. While many synthetic biology innovations have focused on reducing water waste, the prevalence of pollutants in...

Next on the Menu: Cellular Agriculture Could “Domesticate” Any Animal on the Planet

The DNA Industry Is Going Cell-Free

View all posts

Press releases

GreenLight Biosciences opens RNA production facility for the next generation of agricultural products

ROCHESTER, N.Y., Sept. 22, 2021 /PRNewswire/ — GreenLight Biosciences, Inc., a biotechnology company focused on RNA research, design, and manufacturing for human, animal, and plant health, announced the opening of...

Fauna Bio Raises $9 Million to Expand Comparative Genomics Platform for Novel Target Discovery

LifeForce Capital Joins Previous Investors as Company Investigates New Therapies for a Range of Diseases EMERYVILLE, Calif., Sept. 21, 2021 /PRNewswire/ — Fauna Bio, a biotechnology company leveraging animal...

Twist Bioscience Internally-Discovered Single Domain Antibody TB202-3 Shows Potent Binding to Multiple Strains of SARS-CoV-2, Including Alpha, Beta, and Gamma Strains, in Preclinical Studies

– Results Published in Science – – Blinded Analysis Conducted through COVID International Consortium – SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Sep. 23, 2021– Twist Bioscience Corporation (Nasdaq:...

Evonetix Granted Patent for DNA Data Storage and Retrieval Method

Unique approach harnesses Evonetix’s thermally-controlled DNA-on-chip technology to simplify writing, accessing and reading stored DNA Demonstrates potential application of Evonetix’s technology beyond gene synthesis...

Codagenix Announces Safety and Immunogenicity Data from Phase 1 COVID-19 Intranasal Vaccine Trial and Intent to Progress to Phase 2/3 Studies

Novel intranasal vaccine candidate shows promise for immunity against COVID-19 and virus variants FARMINGDALE, N.Y., Sept. 22, 2021 /PRNewswire/ — Codagenix Inc., a clinical-stage biotechnology company pioneering...

Twist Bioscience Collaborates with Deep Learning Experts deepCDR on Antibody Library Design

September 23, 2021 08:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high...

Persephone Biosciences Inc. Announces Collaboration with Janssen Biotech, Inc.

September 21, 2021 11:00 AM Eastern Daylight Time SAN DIEGO, Calif.–(BUSINESS WIRE)–Persephone Biosciences Inc., (“Persephone”) a privately held, data-driven microbiome-focused biotechnology company, today...

Synlogic Announces Positive Phase 2 Data Demonstrating Reduction in Plasma Phenylalanine Levels in Patients with Phenylketonuria

— SYNB1618 demonstrated proof of concept with meaningful reduction of plasma phenylalanine (Phe) levels in an interim analysis of the Phase 2 SynPheny-1 Study — — SYNB1934, an optimized strain of...

Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies

– Anjarium’s versatile platform combines proprietary gene vectors, targeted non-viral delivery technologies and efficient manufacturing solutions to unlock the full potential of gene therapy – Proceeds...

AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines

Partnership combines AbCellera’s AI-powered antibody discovery platform with Moderna’s mRNA technology platform to accelerate the development of mRNA-encoded antibody therapeutics across multiple indications September...

Riffyn Recognized as a Representative Vendor for Intelligent Process Development in 2021 Gartner® Market Guide for Lab Informatics

Riffyn named Representative Vendors of Intelligent Process Development (IPD) and LIMS September 01, 2021 10:50 AM Eastern Daylight Time OAKLAND, Calif.–(BUSINESS WIRE)–Riffyn, the leading SaaS provider of...

Riffyn Identified in 2021 Gartner® Hype Cycle™ for Life Science Manufacturing, Quality and Supply Chain Report Under Two Categories — Bioprocessing Informatics and Enterprise Laboratory Informatics

The leading provider of Intelligent Process Development software in biopharma and biotech was recognized as a Sample Vendor in the 2021 Gartner Hype Cycle for Life Science Manufacturing, Quality and Supply Chain for two...